CRSP insider filings
CRISPR Therapeutics AG — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen CRSP transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 17 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 7 filings by 4 insiders — 93,558 shares, $4,881,673 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 28.
- Largest priced transaction: sale of 47,837 shares @ $49.78 ($2,381,326) by Kulkarni Samarth, filed 2026-10-20.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Kulkarni Samarth — Chief Executive Officer, Director | 4 | — | 2 legs · 51,935 sh · $2,583,193 | 7 |
| KASINGER JAMES R. — General Counsel and Secretary | 4 | — | 3 legs · 13,430 sh · $797,171 | 8 |
| Behbahani Ali — Director | 2 | — | 1 leg · 13,679 sh · $780,935 | 4 |
| George Simeon — Director | 1 | — | 1 leg · 14,514 sh · $720,373 | 2 |
| Silver Andrew Jacob — Chief Financial Officer | 3 | — | — | 3 |
| Patel Naimish — Chief Medical Officer | 1 | — | — | 2 |
| Sakhamuri Sivakesava — Chief Technical Officer | 2 | — | — | 2 |
Recent insider filings — CRISPR Therapeutics AG
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Gift (G): 100,000 @ $0 | EDGAR |
| 2026-11-06 | 4 | Sakhamuri Sivakesava — Chief Technical Officer | Grant/award (A): 90,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-11-02 | 3 | Sakhamuri Sivakesava — Chief Technical Officer | Holdings only — no transactions reported | EDGAR |
| 2026-10-28 | 4 | Silver Andrew Jacob — Chief Financial Officer | Grant/award (A): 18,000 (derivative) @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-10-28 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Grant/award (A): 18,000 (derivative) @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-10-28 | 4 | Patel Naimish — Chief Medical Officer | Grant/award (A): 24,000 (derivative) @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-10-28 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Grant/award (A): 57,500 (derivative) @ $0 · Grant/award (A): 28,750 (derivative) @ $0 | EDGAR |
| 2026-10-21 | 4 | Silver Andrew Jacob — Chief Financial Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-10-21 | 3 | Silver Andrew Jacob — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
| 2026-10-20 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 100,000 · Sale (S): 47,837 @ $49.78 · Option exercise (M): 100,000 (derivative) | EDGAR |
| 2026-10-16 | 4 | George Simeon — Director | Option exercise (M): 30,000 @ $14 · Sale (S): 14,514 @ $49.63 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-10-15 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 8,333 · Sale (S): 4,098 @ $49.26 · Option exercise (M): 8,333 (derivative) | EDGAR |
| 2026-10-15 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 2,113 · Sale (S): 1,040 @ $49.26 · Option exercise (M): 2,113 (derivative) | EDGAR |
| 2026-10-08 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 1,990 @ $13.62 · Sale (S): 1,990 @ $60.04 · Option exercise (M): 1,990 (derivative) @ $0 | EDGAR |
| 2026-09-24 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 10,400 @ $13.62 · Sale (S): 10,400 @ $60.24 · Option exercise (M): 10,400 (derivative) @ $0 | EDGAR |
| 2026-09-21 | 4 | Behbahani Ali — Director | Option exercise (M): 30,000 @ $14 · Sale (S): 13,679 @ $57.09 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-09-21 | 4 | Behbahani Ali — Director | Other (J): 60 @ $0 · Other (J): 15 @ $0 | EDGAR |
| 2026-08-11 | 4 | Prasad Raju — Chief Financial Officer | Gift (G): 750 @ $0 | EDGAR |
| 2026-06-09 | 4 | Fleming Harold Edward — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Rommel Christian — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Treco Douglas A — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Morrison Briggs — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | High Katherine A — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Behbahani Ali — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Greene John — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | George Simeon — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Fardis Maria — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Mahatme Sandesh — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Patel Naimish — Chief Medical Officer | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Prasad Raju — Chief Financial Officer | Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Patel Naimish — Chief Medical Officer | Option exercise (M): 10,000 · Sale (S): 3,786 @ $55.62 · Option exercise (M): 10,000 (derivative) | EDGAR |
| 2026-03-24 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 6,250 · Sale (S): 3,182 @ $46.78 · Grant/award (A): 38,499 (derivative) @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Option exercise (M): 6,250 (derivative) | EDGAR |
| 2026-03-24 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 19,687 · Sale (S): 10,020 @ $46.78 · Grant/award (A): 114,249 (derivative) @ $0 · Grant/award (A): 81,875 (derivative) @ $0 · Option exercise (M): 19,687 (derivative) | EDGAR |
| 2026-03-24 | 4 | Prasad Raju — Chief Financial Officer | Option exercise (M): 6,250 · Sale (S): 3,708 @ $46.78 · Grant/award (A): 38,499 (derivative) @ $0 · Grant/award (A): 27,500 (derivative) @ $0 · Option exercise (M): 6,250 (derivative) | EDGAR |
| 2026-03-24 | 4 | Patel Naimish — Chief Medical Officer | Grant/award (A): 38,499 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Patel Naimish — Chief Medical Officer | Option exercise (M): 8,125 · Sale (S): 3,150 @ $48.26 · Option exercise (M): 8,125 (derivative) | EDGAR |
| 2026-03-17 | 4 | Prasad Raju — Chief Financial Officer | Option exercise (M): 10,000 · Option exercise (M): 6,875 · Sale (S): 5,848 @ $48.26 · Sale (S): 4,021 @ $48.26 · Gift (G): 750 @ $0 · Option exercise (M): 10,000 (derivative) · +1 more | EDGAR |
| 2026-03-17 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 6,875 · Sale (S): 3,450 @ $48.26 · Option exercise (M): 6,875 (derivative) | EDGAR |
| 2026-03-17 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 20,625 · Sale (S): 10,349 @ $48.26 · Option exercise (M): 20,625 (derivative) | EDGAR |
| 2026-03-12 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 5,500 · Sale (S): 2,800 @ $52.80 · Option exercise (M): 5,500 (derivative) | EDGAR |
| 2026-03-12 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 19,250 · Sale (S): 9,798 @ $52.80 · Option exercise (M): 19,250 (derivative) | EDGAR |
| 2026-02-20 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 13,250 · Sale (S): 6,967 @ $52.58 · Option exercise (M): 13,250 (derivative) | EDGAR |
| 2026-02-20 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 3,825 · Sale (S): 2,112 @ $52.58 · Option exercise (M): 3,825 (derivative) | EDGAR |
| 2026-01-27 | 4 | Patel Naimish — Chief Medical Officer | Purchase (P): 1,508 @ $32.96 | EDGAR |
| 2026-01-26 | 4 | Prasad Raju — Chief Financial Officer | Option exercise (M): 34,972 @ $45.15 · Sale (S): 34,972 @ $60.19 · Option exercise (M): 34,972 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Sale (S): 21,433 @ $51.61 · Sale (S): 8,567 @ $52.10 · Sale (S): 60,000 @ $60.23 | EDGAR |
| 2026-01-08 | 4 | Prasad Raju — Chief Financial Officer | Option exercise (M): 23,361 @ $45.15 · Option exercise (M): 6,339 @ $44.31 · Sale (S): 18,933 @ $60.18 · Sale (S): 5,004 @ $60 · Sale (S): 5,763 @ $60.21 · Option exercise (M): 23,361 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-23 | 4 | Prasad Raju — Chief Financial Officer | Sale (S): 3,528 @ $55.10 · Sale (S): 5,472 @ $56.33 · Sale (S): 1,000 @ $56.89 | EDGAR |
| 2025-12-22 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Gift (G): 30,000 @ $0 | EDGAR |
Recent 8-K events — CRISPR Therapeutics AG
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRSP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs